ABS38: Add-on omalizumab significantly improves quality of life in patients with severe persistent allergic (IgE-mediated) asthma

INTRODUCTION: Patients with severe persistent allergic asthma experience frequent serious exacerbations and daily symptoms that diminish health-related quality of life (QoL). AIMS AND OBJECTIVES: To evaluate effects on QoL of add-on omalizumab, an anti-IgE therapy. Subjects and method: A pooled anal...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Prim Care Respir J
Main Authors: Price, D., Fox, H., Surrey, K., Reisner, C.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2006
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6730753/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.137
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares